|
1
|
Huang G, Sun X, Liu D, Zhang Y, Zhang B,
Xiao G, Li X, Gao X, Hu C, Wang M, et al: The efficacy and safety
of anti-PD-1/PD-L1 antibody therapy versus docetaxel for pretreated
advanced NSCLC: A meta-analysis. Oncotarget. 9:4239–4248. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Quintanal-Villalonga Á, Ojeda-Márquez L,
Marrugal Á, Yagüe P, Ponce-Aix S, Salinas A, Carnero A, Ferrer I,
Molina-Pinelo S and Paz-Ares L: The FGFR4-388arg variant promotes
lung cancer progression by N-cadherin induction. Sci Rep.
8:23942018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Gouvinhas C, De Mello RA, Oliveira D,
Castro-Lopes JM, Castelo-Branco P, Dos Santos RS, Hespanhol V and
Pozza DH: Lung cancer: A brief review of epidemiology and
screening. Future Oncol. 14:567–575. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Rios J, Gosain R, Goulart BH, Huang B,
Oechsli MN, McDowell JK, Chen Q, Tucker T and Kloecker GH:
Treatment and outcomes of non-small-cell lung cancer patients with
high comorbidity. Cancer Manag Res. 10:167–175. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Song YJ, Gao XH, Hong YQ and Wang LX:
Direct bilirubin levels are prognostic in non-small cell lung
cancer. Oncotarget. 9:892–900. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lan H, Lu H, Wang X and Jin H: MicroRNAs
as potential biomarkers in cancer: Opportunities and challenges.
Biomed Res Int. 2015:1250942015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Van Schooneveld E, Wildiers H, Vergote I,
Vermeulen PB, Dirix LY and Van Laere SJ: Dysregulation of microRNAs
in breast cancer and their potential role as prognostic and
predictive biomarkers in patient management. Breast Cancer Res.
17:212015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhang XY, Liu DJ, Yuan RB, Zhang DH, Li
SR, Zhang SH and Zhang LY: Low expression of miR-597 is correlated
with tumor stage and poor outcome in breast cancer. Eur Rev Med
Pharmacol Sci. 22:456–460. 2018.PubMed/NCBI
|
|
9
|
Xu C, Zheng Y, Lian D, Ye S, Yang J and
Zeng Z: Analysis of microRNA expression profile identifies novel
biomarkers for non-small cell lung cancer. Tumori. 101:104–110.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Shi GL, Chen Y, Sun Y, Yin YJ and Song CX:
Significance of serum microRNAs in the auxiliary diagnosis of
non-small cell lung cancer. Clin Lab. 63:133–140. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Geraldo MV, Nakaya HI and Kimura ET:
Down-regulation of 14q32-encoded miRNAs and tumor suppressor role
for miR-654-3p in papillary thyroid cancer. Oncotarget.
8:9597–9607. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Teferedegne B, Macauley J, Foseh G,
Dragunsky E, Chumakov K, Murata H, Peden K and Lewis AM Jr:
MicroRNAs as potential biomarkers for VERO cell tumorigenicity.
Vaccine. 32:4799–4805. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hui K, Gao Y, Huang J, Xu S, Wang B, Zeng
J, Fan J, Wang X, Yue Y, Wu S, et al: RASAL2, a RAS
GTPase-activating protein, inhibits stemness and
epithelial-mesenchymal transition via MAPK/SOX2 pathway in bladder
cancer. Cell Death Dis. 8:e26002017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Maertens O and Cichowski K: An expanding
role for RAS GTPase activating proteins (RAS GAPs) in cancer. Adv
Biol Regul. 55:1–14. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wang Z, Wang J, Su Y and Zeng Z: RASAL2
inhibited the proliferation and metastasis capability of
nasopharyngeal carcinoma. Int J Clin Exp Med. 8:18765–18771.
2015.PubMed/NCBI
|
|
16
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta DeltaC(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Fang JF, Zhao HP, Wang ZF and Zheng SS:
Upregulation of RASAL2 promotes proliferation and metastasis, and
is targeted by miR-203 in hepatocellular carcinoma. Mol Med Rep.
15:2720–2726. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Olsen SN, Wronski A, Castaño Z, Dake B,
Malone C, De Raedt T, Enos M, DeRose YS, Zhou W, Guerra S, et al:
Loss of RasGAP tumor suppressors underlies the aggressive nature of
luminal B breast cancers. Cancer Discov. 7:202–217. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Jia Z, Liu W, Gong L and Xiao Z:
Downregulation of RASAL2 promotes the proliferation,
epithelial-mesenchymal transition and metastasis of colorectal
cancer cells. Oncol Lett. 13:1379–1385. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Shen H, Wu X, Zhang Y, Deng G, Ma J, Qu Y
and Zeng S: Expression of RASAL2 in hepatocellular carcinoma and
the clinical significance. Zhong Nan Da Xue Xue Bao Yi Xue Ban.
40:250–255. 2015.(In Chinese). PubMed/NCBI
|
|
21
|
Yan M, Li X, Tong D, Han C, Zhao R, He Y
and Jin X: miR-136 suppresses tumor invasion and metastasis by
targeting RASAL2 in triple-negative breast cancer. Oncol Rep.
36:65–71. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Noto S, Maeda T, Hattori S, Inazawa J,
Imamura M, Asaka M and Hatakeyama M: A novel human RasGAP-like gene
that maps within the prostate cancer susceptibility locus at
chromosome 1q25. FEBS Lett. 441:127–131. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Li N and Li S: RASAL2 promotes lung cancer
metastasis through epithelial-mesenchymal transition. Biochem
Biophys Res Commun. 455:358–362. 2014. View Article : Google Scholar : PubMed/NCBI
|
